China Earthquake Shakes Up Pharma Do-Gooders - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

China Earthquake Shakes Up Pharma Do-Gooders


ePT--the Electronic Newsletter of Pharmaceutical Technology

Chengdu, China (May 22)—The devastating May 12 earthquake that struck the Wen Chuan Sichuan province of China left tens of thousands dead, homes and businesses destroyed, and survivors without basic human needs such as shelter, food, and medicines. The quake also had a significant impact on the local industries of the region. Pharmaceutical companies located within the affected areas are assessing possible damage to facilities and loss of personnel. And in response to the area’s need for medical supplies, pharma companies inside and outside of China are offering help to the people left devastated by the disaster by providing drugs and medical devices.

The majority of pharmaceutical plants located in the region have not yet reported any significant structural damage or loss of personnel because of the quake. Huifeng Bio-Pharmaceutical Technology, Inc (Xi’an, China), a developer and producer of plant extracts and pharmaceutical raw materials, announced that there was no damage to their facilities and workers have returned to the operation. “We are terribly saddened by the loss of life and property in the Sichuan Earthquake. While we are happy to report that neither our employees nor our facilities suffered any harm, Huifeng is prepared to provide support to the victims of this terrible disaster,” company CEO Jing’An Wang stated in a company press release. American Oriental Bioengineering also reported no significant impact. “Our thoughts are with the many victims of China’s earthquake and we are thankful to report that none of our staff was hurt in the tragic events. Our manufacturing, production, and overall operations were not impacted by the earthquake and we do not anticipate any damage-related impact to our sales in the second quarter,” stated Tony Lui, chairman and CEO, in a company press release.

However, not every pharmaceutical company came away unaffected. Tongjitang Chinese Medicines Company, located in Shenzhen, announced on May 14 that the quake damaged the water piping system in its Guiyang facility. The damage compromised the production of the osteoporosis drug Xianling Gubao (XLGB), and the company temporarily halted production.  Xiaochun Wang, Tongjitang’s chief executive office, stated in a company press release, “We are committed to the highest quality levels of production. Currently, we are working diligently to make sure that production will be resumed as soon as conditions allow.”

According to The Associated Press, Doctors Without Borders has reported that pharmacies in the area have been destroyed, leaving a shortage of medicines. The pharmaceutical industry has responded to the devastation with donations of cash and supplies from nearly all pharmaceutical companies, big and small, across the globe and from companies inside China. According to Interfax China, Sinopharm has donated $3.57 million in drugs and medical devices that include ventilators, electrocardiogram monitors, and IV infusion kits. China Pharma Holdings (Hainan) announced on May 16 that it donated over $280,000 of antibiotics, antivirus, and anti-cold products to the relief effort. Jade Pharmaceutical (Hong Kong), a subsidy of AMDL (Tustin, CA), donated more than $70,000 in products to the China Red Cross. Donations continue to arrive to relief organizations in the region from companies and individuals around the world.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here